Latest News and Press Releases

SIOUX FALLS, S.D., May 30, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...

SIOUX FALLS, S.D., May 19, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically...

SIOUX FALLS, S.D., May 16, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...

In study conducted for U.S. Army Medical Research Institute, SAB-183 demonstrated strong immune protection and response against Yersinia pestis infection, which causes plague Findings demonstrate...

-  FDA has approved five of seven sections in a rolling submission required for a New Animal Drug Application (NADA) for Company’s antibody generating DiversitAb™ platform in Transchromosomic (Tc)...

First fully-human multi-epitope binding broadly neutralizing immunoglobulin antibody therapeutic being developed for treatment of high-risk patients demonstrates safety and efficacy in Phase 1 and 2a...

SIOUX FALLS, S.D., May 03, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically...

SIOUX FALLS, S.D., April 26, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...

SAB-176 has now received both Breakthrough and Fast Track designations from FDA – signifying its potential to fundamentally improve influenza treatment and prophylaxis Influenza therapeutic now...

FDA greenlights advancement of SAB-176 Phase 2b trial and manufacturing approach to address influenza strain change SAB-176 is the first fully-human broadly neutralizing immunoglobulin antibody...